These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 17301557)

  • 1. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1.
    Katlama C; Esposito R; Gatell JM; Goffard JC; Grinsztejn B; Pozniak A; Rockstroh J; Stoehr A; Vetter N; Yeni P; Parys W; Vangeneugden T;
    AIDS; 2007 Feb; 21(4):395-402. PubMed ID: 17301557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients.
    Haubrich R; Berger D; Chiliade P; Colson A; Conant M; Gallant J; Wilkin T; Nadler J; Pierone G; Saag M; van Baelen B; Lefebvre E;
    AIDS; 2007 Mar; 21(6):F11-8. PubMed ID: 17413685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48.
    Ortiz R; Dejesus E; Khanlou H; Voronin E; van Lunzen J; Andrade-Villanueva J; Fourie J; De Meyer S; De Pauw M; Lefebvre E; Vangeneugden T; Spinosa-Guzman S
    AIDS; 2008 Jul; 22(12):1389-97. PubMed ID: 18614861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of baseline viral susceptibility on response to darunavir/ritonavir versus control protease inhibitors in treatment-experienced HIV type 1-infected patients: POWER 1 and 2.
    Pozniak A; Opravil M; Beatty G; Hill A; de Béthune MP; Lefebvre E
    AIDS Res Hum Retroviruses; 2008 Oct; 24(10):1275-80. PubMed ID: 18844462
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily darunavir/ritonavir vs. lopinavir/ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis.
    Mills AM; Nelson M; Jayaweera D; Ruxrungtham K; Cassetti I; Girard PM; Workman C; Dierynck I; Sekar V; Abeele CV; Lavreys L
    AIDS; 2009 Aug; 23(13):1679-88. PubMed ID: 19487905
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Final 192-week efficacy and safety of once-daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV-1-infected treatment-naïve patients in the ARTEMIS trial.
    Orkin C; DeJesus E; Khanlou H; Stoehr A; Supparatpinyo K; Lathouwers E; Lefebvre E; Opsomer M; Van de Casteele T; Tomaka F
    HIV Med; 2013 Jan; 14(1):49-59. PubMed ID: 23088336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prediction of clinical benefits of ritonavir-boosted TMC114 from treatment effects on CD4 counts and HIV RNA.
    Hill A; Montaner J; Smith C
    HIV Med; 2007 May; 8(4):234-40. PubMed ID: 17461851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relative antiviral efficacy of ritonavir-boosted darunavir and ritonavir-boosted tipranavir vs. control protease inhibitor in the POWER and RESIST trials.
    Hill A; Moyle G
    HIV Med; 2007 May; 8(4):259-64. PubMed ID: 17461854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials.
    Clotet B; Bellos N; Molina JM; Cooper D; Goffard JC; Lazzarin A; Wöhrmann A; Katlama C; Wilkin T; Haubrich R; Cohen C; Farthing C; Jayaweera D; Markowitz M; Ruane P; Spinosa-Guzman S; Lefebvre E;
    Lancet; 2007 Apr; 369(9568):1169-78. PubMed ID: 17416261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV-1 RNA copies/mL at baseline.
    Arribas JR; Clumeck N; Nelson M; Hill A; van Delft Y; Moecklinghoff C
    HIV Med; 2012 Aug; 13(7):398-405. PubMed ID: 22413874
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
    Cahn P; Fourie J; Grinsztejn B; Hodder S; Molina JM; Ruxrungtham K; Workman C; Van De Casteele T; De Doncker P; Lathouwers E; Tomaka F
    AIDS; 2011 Apr; 25(7):929-39. PubMed ID: 21346512
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of virologic failure patients on darunavir/ritonavir in treatment-experienced patients.
    De Meyer S; Lathouwers E; Dierynck I; De Paepe E; Van Baelen B; Vangeneugden T; Spinosa-Guzman S; Lefebvre E; Picchio G; de Béthune MP
    AIDS; 2009 Sep; 23(14):1829-40. PubMed ID: 19474650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
    J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-naïve and -experienced patients.
    Boffito M; Miralles D; Hill A
    HIV Clin Trials; 2008; 9(6):418-27. PubMed ID: 19203907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMC114/ritonavir substitution for protease inhibitor(s) in a non-suppressive antiretroviral regimen: a 14-day proof-of-principle trial.
    Arastéh K; Clumeck N; Pozniak A; Lazzarin A; De Meyer S; Muller H; Peeters M; Rinehart A; Lefebvre E;
    AIDS; 2005 Jun; 19(9):943-7. PubMed ID: 15905675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    Arribas JR; Horban A; Gerstoft J; Fätkenheuer G; Nelson M; Clumeck N; Pulido F; Hill A; van Delft Y; Stark T; Moecklinghoff C
    AIDS; 2010 Jan; 24(2):223-30. PubMed ID: 20010070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96.
    Arastéh K; Yeni P; Pozniak A; Grinsztejn B; Jayaweera D; Roberts A; Hoy J; De Meyer S; Vangeneugden T; Tomaka F
    Antivir Ther; 2009; 14(6):859-64. PubMed ID: 19812449
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Week 96 efficacy, virology and safety of darunavir/r versus lopinavir/r in treatment-experienced patients in TITAN.
    Bánhegyi D; Katlama C; da Cunha CA; Schneider S; Rachlis A; Workman C; De Meyer S; Vandevoorde A; Van De Casteele T; Tomaka F
    Curr HIV Res; 2012 Mar; 10(2):171-81. PubMed ID: 22339125
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
    Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
    Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subgroup analysis of virological response rates with once- and twice-daily darunavir/ritonavir in treatment-experienced patients without darunavir resistance-associated mutations in the ODIN trial.
    Sension M; Cahn P; Domingo P; Hodder S; Opsomer M; Lathouwers E; Van de Casteele T; Tomaka F
    HIV Med; 2013 Aug; 14(7):437-44. PubMed ID: 23480640
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.